Kennedy Jr. as a defendant, asked the courts to rule against plaintiffs Eli Lilly, Bristol Myers Squibb and Novartis Pharmaceuticals in one of the ongoing consolidated lawsuits related to a 340B ...

In their joint lawsuit, Amgen, Eli Lilly and Company, and UCB claim several Nevada STD clinics were unlawfully qualified for the federal drug discount program, 340B, giving them access to millions ...

In just 10 years, annual 340B purchases grew more than 700%, from $7.5 billion in 2013 to $53.7 billion in 2022. Factors underlying this growth include. Exponential growth in participation by non ...

All North Dakotans surely know the adage, “If it ain’t broke, don’t fix it.” Well, some North Dakota state lawmakers are test-driving a new concept: “If it is broke, pretend it’s not.” ...

The 340B Drug Discount Program was designed to help safety-net providers make drugs available to low-income patients and earn revenue. Drug manufacturers have put restrictions on which pharmacies ...

The 340B program, intended to lower drug costs for low-income patients, often benefits hospitals more than patients. A lack of transparency allows some hospitals to profit from the program instead ...

However, managing a 340B program is complex and time consuming given the requirement to maintain compliance. Participating providers struggle to verify patient eligibility, implement robust ...

The bill (LB168) from Sen. Brian Hardin of Gering would prohibit pharmaceutical companies from restricting or interfering in the sale of drugs included in the 340B program. Under 340B, which was ...